Cargando…
Vutiglabridin Modulates Paraoxonase 1 and Ameliorates Diet-Induced Obesity in Hyperlipidemic Mice
Vutiglabridin is a clinical-stage synthetic small molecule that is being developed for the treatment of obesity and its target proteins have not been fully identified. Paraoxonase-1 (PON1) is an HDL-associated plasma enzyme that hydrolyzes diverse substrates including oxidized low-density lipoprotei...
Autores principales: | Sulaiman, Dawoud, Choi, Leo Sungwong, Lee, Hyeong Min, Shin, Jaejin, Kim, Dong Hwan, Lee, Keun Woo, Eftekhari, Pierre, Quartier, Angélique, Park, Hyung Soon, Reddy, Srinivasa T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135725/ https://www.ncbi.nlm.nih.gov/pubmed/37189434 http://dx.doi.org/10.3390/biom13040687 |
Ejemplares similares
-
Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation
por: Shin, Gu-Choul, et al.
Publicado: (2022) -
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
por: Na, Joo Young, et al.
Publicado: (2022) -
Synthetic Glabridin Derivatives Inhibit LPS-Induced Inflammation via MAPKs and NF-κB Pathways in RAW264.7 Macrophages
por: Shin, Jaejin, et al.
Publicado: (2023) -
Berberine Ameliorates Brain Inflammation in Poloxamer 407-Induced Hyperlipidemic Rats
por: Kim, Mia, et al.
Publicado: (2019) -
Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice
por: Charles-Schoeman, Christina, et al.
Publicado: (2020)